Note 16 - Subsequent Events On May 4, 2
Post# of 36537
(Total Views: 347)
Posted On: 06/21/2021 4:14:12 PM
Note 16 - Subsequent Events
On May 4, 2021, the Company issued 300,000 shares of common stock to Oasis for net proceeds of $71,387.
On May 10, 2021, the Company entered into a Securities Purchase Agreements pursuant to which the Company sold a convertible note bearing interest at 12% per year in the principal amount of $1,085,000. The purchase price of the note was $1,000,000 and the remaining $85,000 of principal represents original issue discount. Additionally, the Company issued 700,000 shares of common stock which was recorded as debt discount.
On May 13, 2021, the Company issued 400,000 shares of common stock to Oasis for net proceeds of $91,323.
On May 20, 2021, Generex executed a Project Addendum (“Addendum”) to an existing agreement on with PPD Development, L.P. for its compensation performance of services under this Addendum, PPD shall receive a total sum anticipated not to exceed $8,901,715 of which $3,168,646 shall be direct fees, and of which $5,733,069 shall be handled as pass through costs. The pass-through costs are estimated and may vary as circumstances require.
On June 1, 2021, the Company issued 400,000 shares of common stock to Oasis for net proceeds of $83,964.
On June 3, 2021, the Company entered into a Securities Purchase Agreements pursuant to which the Company sold a convertible note bearing interest at 6% per year in the principal amount of $324,000. The purchase price of the note was $300,000 and the remaining $24,000 of principal represents original issue discount. In conjunction, the Company issued 206,182 shares of common stock which was recorded as debt discount. In conjunction the Company granted warrants to purchase 353,455 shares of common stock at $0.60 per share.
On June 14, 2021, the company issued 250,000 shares of common stock to oasis for net proceeds of $52,477.
On May 4, 2021, the Company issued 300,000 shares of common stock to Oasis for net proceeds of $71,387.
On May 10, 2021, the Company entered into a Securities Purchase Agreements pursuant to which the Company sold a convertible note bearing interest at 12% per year in the principal amount of $1,085,000. The purchase price of the note was $1,000,000 and the remaining $85,000 of principal represents original issue discount. Additionally, the Company issued 700,000 shares of common stock which was recorded as debt discount.
On May 13, 2021, the Company issued 400,000 shares of common stock to Oasis for net proceeds of $91,323.
On May 20, 2021, Generex executed a Project Addendum (“Addendum”) to an existing agreement on with PPD Development, L.P. for its compensation performance of services under this Addendum, PPD shall receive a total sum anticipated not to exceed $8,901,715 of which $3,168,646 shall be direct fees, and of which $5,733,069 shall be handled as pass through costs. The pass-through costs are estimated and may vary as circumstances require.
On June 1, 2021, the Company issued 400,000 shares of common stock to Oasis for net proceeds of $83,964.
On June 3, 2021, the Company entered into a Securities Purchase Agreements pursuant to which the Company sold a convertible note bearing interest at 6% per year in the principal amount of $324,000. The purchase price of the note was $300,000 and the remaining $24,000 of principal represents original issue discount. In conjunction, the Company issued 206,182 shares of common stock which was recorded as debt discount. In conjunction the Company granted warrants to purchase 353,455 shares of common stock at $0.60 per share.
On June 14, 2021, the company issued 250,000 shares of common stock to oasis for net proceeds of $52,477.
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼